Hearing impairment amongst people with Osteogenesis Imperfecta in Germany
European Archives of Oto-Rhino-Laryngology · 2025
DOI: 10.1007/s00405-024-08983-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von A Felicio-Briegel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. Axelle.Felicio@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Osteogenesis Imperfecta, Hearing Loss. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ATMOS MedizinTechnik GmbH & Co. KG, PATH MEDICAL GmbH, Klinikum der Universität München.
Abstract (Originalsprache)
Introduction
Hearing impairment concerns a relevant percentage of individuals with Osteogenesis Imperfecta (OI). When looking at the current literature, the percentage of affected individuals with OI varies greatly from 32 to 58% of patients having mild OI and 21% to 27% of patients having moderate to severe OI. Little is known about the German population with OI.
Method
The goal of this study was to detect how many patients with OI, who visited the annual meeting of the German Association for Osteogenesis Imperfecta in 2023, proved to have a hearing impairment. In this prospective, cross-sectional study, each included individual obtained ear microscopy, audiometry, stapedius reflexes, tympanometry, and OAEs. Furthermore, each patient was asked a set of questions concerning the medical history.
Results
Of the included patients, 33% had hearing impairment . A significant difference was found for the mean air–bone gap (ABG) as well as the hearing threshold of the right ears. The difference was found between OI type III and IV (p = 0.0127) for the mean ABG and OI type I and IV (p = 0.0138) as well as III and IV (p = 0.0281) for the hearing threshold. Spearman’s rank correlation showed a high correlation between age and hearing threshold. Of the patients between 40 and 50 years old, 56% had hearing loss.
Conclusion
Hearing loss in individuals with OI is still a relevant problem, especially age-related in OI type I. Audiometry should be performed at least when individuals experience subjective hearing loss. The implementation of a screening starting at 40 years should be discussed and studied.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. Axelle.Felicio@med.uni-muenchen.de.
- Department of Otorhinolaryngology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
- Department of Orthopedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
- Department of Pulmonology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Förderung
- ATMOS MedizinTechnik GmbH & Co. KG
- PATH MEDICAL GmbH
- Klinikum der Universität München
Zitieren
APA
Felicio-Briegel, A., Müller, J., Pollotzek, M., Neuling, M., Polterauer, D., Gantner, S., Simon, J., Briegel, I., & Simon, F. (2025). Hearing impairment amongst people with Osteogenesis Imperfecta in Germany. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08983-5
Vancouver
Felicio-Briegel A, Müller J, Pollotzek M, Neuling M, Polterauer D, Gantner S, et al. Hearing impairment amongst people with Osteogenesis Imperfecta in Germany. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-024-08983-5
BibTeX
@article{FelicioBriegel2025,
author = {Felicio-Briegel, A and Müller, J and Pollotzek, M and Neuling, M and Polterauer, D and Gantner, S and Simon, J and Briegel, I and Simon, F},
title = {Hearing impairment amongst people with Osteogenesis Imperfecta in Germany},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
doi = {10.1007/s00405-024-08983-5}
}
EUVIMED